SEM SELECT MEDICAL HOLDINGS CORP Insider Trading

Director Parvinderjit S. Khanuja buys 21,000 SEM shares at $15.02; holdings rise 47.6% to 65.1K; stock down 64.0% from 52-week high.

Director Parvinderjit S. Khanuja purchased 21,000 shares at $15.02, materially expanding his stake by 47.6% to 65,089 shares post-transaction. The transaction occurs against a backdrop of significant price deterioration: the stock is down 64.0% from its 52-week high of $40.20 and down 8.6% over the preceding 30 days, while the company faces a -22.2% annual revenue decline. The modest P/E of 10.70 and low current price of $14.45 relative to the transaction price of $15.02 suggest the purchase preceded further near-term weakness. This transaction represents a substantial commitment from a director during a period when the company's financial trajectory has weakened materially, warranting closer examination of whether board-level confidence in turnaround prospects is strengthening or if other strategic considerations are at play.

CEO David S. Chernow sold 225,000 shares of SEM at $18.00 for $4.0M on 2025-04-28

David S. Chernow, the CEO of Select Medical Holdings, sold 225,000 shares representing -23.9% of his pre-transaction holdings of 939,516 shares, leaving him with 714,516 shares post-sale. The sale occurred at $18.00 per share when the stock was trading -54.2% from its 52-week high of $40.20, amid a backdrop of -22.2% annual revenue decline year-over-year. The company's P/E of 9.64 suggests a low valuation multiple, though the recent 30-day stock performance was +9.6%, contrasting with the weaker 90-day change of -6.1%. The material reduction in the CEO's ownership stake during a period of significant revenue contraction and depressed stock valuation merits investor attention to understand the transaction rationale and its implications for management confidence in near-term operations.

Executive Chairman ORTENZIO ROBERT A sells entire 3,804,805 share position in SEM for $74,383,937.75 on 2024-11-26

ORTENZIO ROBERT A liquidated his complete shareholding of 3,804,805 shares at $19.55, realizing $74,383,937.75 and reducing post-transaction holdings to 0 shares. The sale occurs after a significant drawdown: the stock has fallen -47.5% from its 52-week high of $40.20 and declined -35.7% over the prior 30 days and -41.5% over 90 days. At the same ticker (SEM), his prior 5 sales all generated positive 90-day returns (ranging from +13.3% to +26.3%), meaning the stock rose after each of those exits; his timing pattern at SEM shows 0 of 5 prior sells were well-timed, indicating these past sales preceded continued upside. The company's fundamentals remain intact: $1.8B in quarterly revenue, $55.6M net income, +5.2% annual revenue growth, and a 9.91 P/E ratio valued at $2.7B market cap. The full liquidation following severe price depreciation and the historical pattern of his prior SEM sales occurring before further gains raise questions about exit rationale given the underlying business health and valuation multiples.